The stock of Albireo Pharma, Inc. (NASDAQ:ALBO) is a huge mover today! The stock decreased 13.53% or $4.14 on November 23, hitting $26.45. About 106,586 shares traded hands or 121.49% up from the average. Albireo Pharma, Inc. (NASDAQ:ALBO) has risen 109.92% since April 22, 2016 and is uptrending. It has outperformed by 104.51% the S&P500.
The move comes after 9 months negative chart setup for the $65.41 million company. It was reported on Nov, 24 by Barchart.com. We have $25.13 PT which if reached, will make NASDAQ:ALBO worth $3.27M less.
Analysts await Albireo Pharma, Inc. (NASDAQ:ALBO) to report earnings on December, 15.
According to Zacks Investment Research, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States.”
More recent Albireo Pharma, Inc. (NASDAQ:ALBO) news were published by: Quotes.Wsj.com which released: “News Albireo Pharma Inc.ALBO” on November 03, 2016. Also Streetinsider.com published the news titled: “Form 3 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Sermon Charles” on November 07, 2016. Marketwired.com‘s news article titled: “Biodel Inc. and Albireo Limited Agree to Combine” with publication date: May 25, 2016 was also an interesting one.
ALBO Company Profile
Albireo Pharma, Inc., formerly Biodel Inc., incorporated on December 8, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company’s clinical pipeline includes over two Phase II product candidates and one Phase III product candidate. The Company’s pipeline includes A4250, A3384 and Elobixibat.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.